You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
| Title |
Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients*
|
|---|---|
| Published in |
Anais Brasileiros de Dermatologia, January 2016
|
| DOI | 10.1590/abd1806-4841.20164292 |
| Pubmed ID | |
| Authors |
João Roberto Antonio, Jessica Sanmiguel, Giovana Viotto Cagnon, Marília Silveira Faeda Augusto, Moacir Fernandes de Godoy, Eurides Maria Oliveira Pozetti |
| Abstract |
Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature. To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis). Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment. 168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events. Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 14% |
| Student > Master | 8 | 12% |
| Researcher | 7 | 11% |
| Student > Bachelor | 6 | 9% |
| Student > Postgraduate | 5 | 8% |
| Other | 14 | 22% |
| Unknown | 16 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 12% |
| Unspecified | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Computer Science | 2 | 3% |
| Other | 6 | 9% |
| Unknown | 20 | 31% |